INS and diabetes mellitus: At 35 weeks of age, only 39% and 33% (7/18 and 6/18) of the NOD mice that received CTB-INS (group 1) or CTB-Ins-GFP (group 2) fusion protein developed diabetes compared with 67% and 70% (12/18 and 7/10) of those fed the CTB-GFP peptide (group 3) or Saline (group 4), respectively (groups 1 and 2 versus groups 3 and 4, P = .0276; group 1 versus group 2, P = .9683; Figure 5).